Cavalier Etienne, Delanaye Pierre, Nyssen Laurent, Souberbielle Jean-Claude
Department of Clinical Chemistry, CHU de Liège, Liège, Belgium; University of Liège, Liège, Belgium.
Department of Nephrology, Dialysis, Transplantation, CHU de Liège, 4000 Liège, Belgium.
Ann Endocrinol (Paris). 2015 May;76(2):128-33. doi: 10.1016/j.ando.2015.03.018. Epub 2015 Apr 25.
Even if the first assay for parathyroid hormone (PTH) was published in the early 1960s, its determination remains a challenge even today. Indeed, in the circulation, PTH is present in its active form (PTH 1-84), but many PTH fragments can also be present. These fragments accumulate when renal function declines and are recognized, at different extents, by the 2nd generation ("intact") PTH assays that are widely used in the clinical laboratories. Some assays, called "3rd generation PTH" do not recognize these fragments, but are not available everywhere. Hence, different problems are also linked with PTH determination. Among them, one can cite the lack of a reference method, the lack of standardization of the assays and, sometimes, the lack of consistent reference range. We can also point out stability problems and a large intra-individual variation. A workgroup is working on these problems under the auspices of the IFCC and we hope that some of these problems will be resolved in the next years. In this article, we will discuss all the possible issues of PTH determination.
即便甲状旁腺激素(PTH)的首次检测方法于20世纪60年代初就已发表,但即便在今天,其测定仍是一项挑战。实际上,在循环系统中,PTH以其活性形式(PTH 1-84)存在,但也可能存在许多PTH片段。当肾功能下降时,这些片段会累积,并且在不同程度上被临床实验室广泛使用的第二代(“完整”)PTH检测方法识别。一些被称为“第三代PTH”的检测方法不识别这些片段,但并非在所有地方都能获得。因此,PTH测定还存在不同的问题。其中,可以列举出缺乏参考方法、检测方法缺乏标准化,以及有时缺乏一致的参考范围。我们还可以指出稳定性问题和较大的个体内变异。一个工作组正在国际临床化学和检验医学联合会(IFCC)的支持下致力于解决这些问题,我们希望其中一些问题能在未来几年得到解决。在本文中,我们将讨论PTH测定所有可能存在的问题。